Dabrafenib Plus Trametinib in Patients With BRAFV600E-Mutant Low-Grade and High-Grade Glioma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
Lancet Oncol 2021 Nov 24;[EPub Ahead of Print], PY Wen, A Stein, M van den Bent, J De Greve, A Wick, FYFL de Vos, N von Bubnoff, ME van Linde, A Lai, GW Prager, M Campone, A Fasolo, JA Lopez-Martin, TM Kim, WP Mason, RD Hofheinz, JY Blay, DC Cho, A Gazzah, D Pouessel, J Yachnin, A Boran, P Burgess, P Ilankumaran, E Gasal, V SubbiahFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.